Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7326/0003-4819-116-5-391 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combination treatment of extracorporeal photopheresis and belumosudil for chronic graft-versus-host disease.
Arch Dermatol Res
January 2025
Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.
Generation of Human Chimeric Antigen Receptor Regulatory T Cells.
J Vis Exp
January 2025
Department of Microbiology and Immunology, Medical University of South Carolina; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina; Hollings Cancer Center, Medical University of South Carolina;
Chimeric antigen receptor (CAR) T-cell therapy has reshaped the face of cancer treatment, leading to record remission rates in previously incurable hematological cancers. These successes have spurred interest in adapting the CAR platform to a small yet pivotal subset of CD4 T cells primarily responsible for regulating and inhibiting the immune response, regulatory T cells (Tregs). The ability to redirect Tregs' immunosuppressive activity to any extracellular target has enormous implications for creating cell therapies for autoimmune disease, organ transplant rejection, and graft-versus-host disease.
View Article and Find Full Text PDFPost hematopoietic stem cell transplant (HSCT) outcomes in pediatric intensive care unit, experience from a referral center for cellular therapy and hematopoietic stem cell transplantation.
Hematol Oncol Stem Cell Ther
January 2025
Pediatric Critical Care consultant, Pediatric Critical Care department, Ad Diriyah hospital, Riyadh, Saudi Arabia.
Background: Patients who underwent hematopoietic stem cell transplantation (HSCT) are considered at high risk for pediatric intensive care unit (PICU) admission. Therefore, this study aimed to assess outcomes and mortality-related risk factors among pediatric HSCT recipients admitted to the PICU.
Methods: This retrospective cohort study was conducted at a Saudi Arabian tertiary care center and involved pediatric patients (aged 4 weeks to 14 years) who underwent HSCTs between January 2015 and December 2019 and were admitted to the PICU.
Low incidence of primary graft failure with bendamustine, fludarabine, and busulfan conditioning prior to haploidentical allogeneic hematopoietic cell transplantation.
Hematol Oncol Stem Cell Ther
January 2025
R.M. Gorbacheva Memorial Institute of Children Hematology and Transplantation, State Medical University Named I.P. Pavlov, Saint-Petersburg, Russian Federation.
The outcomes of haploidentical hematopoietic cell transplantation (haplo-HCT) have improved with the implication of new in vivo and ex vivo graft-versus-host disease (GVHD) prophylaxis regimens. However, primary graft failure is still reported more frequently in haplo-HCT compared to a matched donor HCT. We conducted a pilot study (NCT04942730) to evaluate the impact of adding bendamustine to fludarabine and busulfan conditioning on engraftment after haplo-HCT.
View Article and Find Full Text PDFTransfusion-associated graft-versus-host disease (TA-GVHD) and graft-versus-host disease (GVHD): Pathophysiology and management (contrasted and compared).
Hematol Oncol Stem Cell Ther
January 2025
Hematology Laboratory-Blood Bank, Aretaieion Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Transfusion of blood products is a common lifesaving medical procedure in clinical practice. However, it poses the risk of potential adverse reactions for the recipient. Transfusion-associated graft-versus-host-disease (TA-GVHD) is a rare adverse event, fatal in >90% of cases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!